BCG vaccination against tuberculosis: past disappointments and future hopes

Area of Science:

• Immunology
• Vaccinology
• Infectious Diseases

Background:

• The bacille Calmette-Guérin (BCG) vaccine is a widely used tuberculosis preventative, with over three billion doses administered globally.
• Despite its widespread use, BCG exhibits significant variability in its efficacy in protecting humans against tuberculosis.

Purpose of the Study:

• To investigate the underlying causes for the inconsistent protective effects of BCG vaccination.
• To explore potential strategies for enhancing the effectiveness of BCG vaccination against tuberculosis.

Main Methods:

• Literature review of existing studies on BCG vaccine efficacy and variability.
• Analysis of factors contributing to differential immune responses to BCG.
• Exploration of novel approaches and modifications to improve BCG vaccine performance.

Main Results:

• BCG's variable efficacy is influenced by a complex interplay of host genetics, environmental factors, and pathogen-specific characteristics.
• Existing data suggests that specific strains of BCG and differing administration routes may impact protection levels.
• Several promising avenues for vaccine improvement are being explored, including novel formulations and combination therapies.

Conclusions:

• Understanding the reasons for BCG's variable efficacy is crucial for optimizing tuberculosis control strategies.
• Further research into host-pathogen interactions and vaccine technology is needed to enhance BCG's protective capabilities.
• Developing improved BCG vaccines or alternative strategies is essential to combat the global burden of tuberculosis.